Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment Meeting Abstract
| Authors: | Iwata, H.; Baselga, J.; Campone, M.; Arteaga, C. L.; Cortes, J.; Jonat, W.; De Laurentiis, M.; Ciruelos, E.; Janni, W.; Bachelot, T.; Lonning, P. E.; Ma, C.; O'Regan, R.; Di Tomaso, E.; Bharani-Dharan, B.; Duval, V.; Lau, H.; Germa, C.; Urban, P.; Di Leo, A. |
| Abstract Title: | Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419605480 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.TPS650 |
| Notes: | Meeting Abstract: TPS650^ -- Source: Wos |
